Entresto Uptitration Frequency
Entresto (sacubitril/valsartan) should be uptitrated every 2-4 weeks in adults and every 2 weeks in pediatric patients, doubling the dose at each step until reaching the target dose of 97/103 mg twice daily (or maximum tolerated dose). 1
Standard Uptitration Protocol
Adults with Heart Failure
- Starting dose: 49/51 mg twice daily
- Uptitration interval: Every 2-4 weeks 1
- Target dose: 97/103 mg twice daily
- Monitoring: Check blood pressure, renal function, and electrolytes 1-2 weeks after initiation and after each dose increase 2
The FDA label explicitly states to "double the dose of ENTRESTO after 2 to 4 weeks to the target maintenance dose" 1. This recommendation is reinforced by ACC/AHA guidelines, which specify that GDMT medications should be "adjusted no more frequently than every 2 weeks to target doses" 3.
Pediatric Patients (≥1 year old)
- Uptitration interval: Every 2 weeks 1
- Three-step titration: Starting dose → Second dose → Final dose
- Doses are weight-based, with specific recommendations for patients <40 kg, 40-50 kg, and ≥50 kg 1
Special Populations Requiring Modified Uptitration
Patients Not Previously on ACEi/ARB or on Low Doses
Start at half the usual starting dose (24/26 mg twice daily), then uptitrate every 2-4 weeks in adults or every 2 weeks in pediatric patients 1. The 2021 ACC Expert Consensus emphasizes that patients with severe renal impairment (eGFR <30) or moderate hepatic impairment should start at 24/26 mg twice daily and uptitrate every 2-4 weeks 2.
Patients with Low Blood Pressure
The TITRATION trial demonstrated that gradual uptitration over 6 weeks (conservative approach) was better tolerated than rapid 3-week uptitration (condensed approach) in patients with baseline systolic BP 100-110 mmHg 4, 5. Specifically:
- 80% achieved target dose with 6-week uptitration vs. 69% with 3-week uptitration in low BP patients 5
- For patients with SBP 100-110 mmHg, consider extending uptitration intervals toward the 4-week end of the recommended range
Monitoring During Uptitration
Critical monitoring timepoints 2, 6:
- 1-2 weeks after initiation: Check BP, creatinine, potassium
- 1 week and 4 weeks after each dose increase: Repeat labs
- Monthly for 3 months after reaching maintenance dose, then every 3 months if stable
Red Flags Requiring Dose Adjustment or Hold
- Hypotension: SBP <80 mmHg with symptoms 7
- Renal dysfunction: Creatinine increase >50% or >266 μmol/L (3.0 mg/dL) 8
- Hyperkalemia: Potassium >5.5 mmol/L 2, 6
Clinical Context from Recent Evidence
The 2021 CCS/CHFS guidelines strongly support in-hospital initiation with early uptitration 9. The PIONEER-HF trial showed that patients who started ARNI in-hospital had lower rates of HF hospitalization or CV mortality (13.0% vs 18.1%) compared to those who delayed initiation 9. This supports aggressive but monitored uptitration.
However, real-world data reveals a gap: only 27-45% of patients achieve target dose within 6 months in clinical practice 10, 4. The main barriers are:
- Slower uptitration than trial protocols (54.7% of failures) 10
- Hypotension (25.3%) 10
- Patient non-compliance (4%) 10
The PREMIER study demonstrated that uptitration to >24/26 mg twice daily yielded significantly greater NT-proBNP reduction (-51%) compared to no uptitration (-39%) or ACEi/ARB (-32%) 11, emphasizing the importance of achieving higher doses when tolerated.
Practical Algorithm
- Week 0: Start 49/51 mg BID (or 24/26 mg BID if ACEi/ARB-naive or special population)
- Week 2-4: Check labs; if tolerated, double to 97/103 mg BID (or 49/51 mg if started low)
- Week 4-8: If started at 24/26 mg, uptitrate to 97/103 mg BID
- Ongoing: Monitor BP, renal function, potassium at each visit until stable
Common pitfall: Abandoning uptitration due to asymptomatic hypotension. The 2025 ESC HFA consensus emphasizes that asymptomatic low BP in stable patients does not require dose reduction 7. Only symptomatic hypotension (dizziness, fatigue) with SBP <80 mmHg warrants intervention.